HRAS lies downstream of FGFR3, and increased signaling following mutations in HRAS are correlated with enhanced susceptibility to bladder cancer and other abnormalities in patients with Costello syndrome7–12. This evidence concerns the gene FGFR3 and urinary bladder cancer.